Yifang Biology: A new subsidiary has opened a special account and signed a four-party supervision agreement for fundraising.

Yifang Biotechnology announced that the company's initial public offering raised a net amount of 1.982 billion yuan. On July 2, 2026, the company agreed to establish Yiqi Biotechnology, a wholly-owned subsidiary, as the main body for the "new drug development project" and open a special account for raising funds. Recently, Yiqi Biotechnology opened a special account at the Shanghai branch of China Merchants Bank, and signed the "Four-Party Supervision Agreement for the Special Account for Raising Funds" with the company, the sponsoring institution Citic Securities, and the Shanghai branch of China Merchants Bank. As of July 16, the balance in the special account was 0 yuan.